PDUFA V: BIO Comments on FDA's NME Review Program Assessment

Aug 5 2012


Accelerated Approval: BIO Comments on pCR in Neoadjuvant Treatment for Breast Cancer

Jul 29 2012


The 10th Anniversary of the Sarbanes-Oxley Act, Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals

Jul 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Development of the Joint Strategic Plan on Intellectual Property Enforcement: BIO Comments

Jul 25 2012


BIO's Letter of Support for the Intellectual Property Attaché Act

Jul 11 2012


Agricultural Biotechnology: Federal Agriculture Reform and Risk Management Act of 2012

Jul 10 2012
BIO, along with other major agriculture organizations, sent a letter in support of provisions in the FARRM bill to Chairman Frank Lucas and Ranking Member Collin Peterson on July 6.

REMS: BIO Comments on Risk Evaluation and Mitigation Strategy Assessments: Social Science Methodologies to Assess Goals Related to Knowledge

Jul 6 2012


Unique Names for Biosimilar Products: Letter to Commissioner Hamburg

Jul 3 2012

IP Attache Program: BIO's Congressional Hearing Comments

Jun 27 2012
The U.S. Intellectual Property Rights Attaché Program has had significant success and holds immense promise in helping to enhance IP protection abroad for U.S. interests.

Oppose Costly & Confusing Labeling Amendment to the Agriculture Reform, Food and Jobs Act of 2012

Jun 21 2012
Senators Sanders and Boxer have introduced an amendment that will result in costly and extreme food labeling requirements.